Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID)

NCT02847260 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG: Remodulin

Sponsor

United Therapeutics